CD38 and Miyoshi myopathy: Similarly, BITE therapies targeting CD38/CD3, such as AMG 424, have shown strong MM cell eradication but carry a risk of ‘off-tumor’ T-cell cytotoxicity, potentially impacting normal B, T, and NK cells [39].